Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24443104 | 0.79 | — | — | |
| SCHEMBL5645553 | 0.78 | CTH (0.35) | CTHDDAH1 | |
| SCHEMBL5643644 | 0.78 | CTH (0.40) | CTHDDAH1ALDH1A1 | |
| SCHEMBL24443097 | 0.78 | CTH (0.36) | CTHDDAH1ALDH1A1 | |
| SCHEMBL20651769 | 0.78 | CTH (0.36) | CTHCHRM2CHRM1RRM1RRM2B | |
| SCHEMBL21769501 | 0.76 | CTH (0.37) | CTHDDAH1RARBALDH1A1 | |
| SCHEMBL16851584 | 0.74 | CTH (0.33) | CTHDDAH1 | |
| SCHEMBL16851540 | 0.74 | CTH (0.33) | CTHDDAH1 | |
| SCHEMBL16851652 | 0.74 | CTH (0.33) | CTHDDAH1 | |
| SCHEMBL16851679 | 0.74 | CTH (0.33) | CTHDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389036-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR?) AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-12-08 | — | — | US | disclosed |
| US-9051265-B2 | N-benzylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-09 | — | — | US | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | PPARG, CDK5R1, CDK5 | CTH 4406/4885CHRM2 2478/4885CHRM1 1762/4885 |
| US-20220389036-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR?) AND METHODS OF USE | PPARG, PPARA, PPARD | CTH 3709/4885CHRM2 2918/4885CHRM1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.